Acquisitions and License Agreements (Schedule of Intangible Assets Acquired) (Details) - USD ($) $ in Millions	Sep. 25, 2015	Apr. 16, 2015	Aug. 14, 2014	Mar. 19, 2014	Oct. 01, 2012
Therakos
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired	$ 1,019.7
Intangible assets	1,170.0
Therakos | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired	$ 1,170.0
Intangible assets acquired, weighted-average useful life	15 years
Ikaria
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired		$ 1,253.6
Intangible assets		1,971.0
Amortizable intangible assets acquired		1,971.0
Ikaria | In-process research and development
Intangible Assets Acquired as Part of Business Combination [Line Items]
Amortizable intangible assets acquired		$ 81.0
Ikaria | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life		15 years
Amortizable intangible assets acquired		$ 1,820.0
Ikaria | Trademarks
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life		22 years
Amortizable intangible assets acquired		$ 70.0
Cash flow discount rate		14.50%
Questcor Pharmaceuticals, Inc.
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired			$ 5,786.5
Intangible assets			5,601.1
Questcor Pharmaceuticals, Inc. | In-process research and development
Intangible Assets Acquired as Part of Business Combination [Line Items]
Indefinite lived intangible assets acquired			$ 218.3
Cash flow discount rate			16.00%
Questcor Pharmaceuticals, Inc. | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life			18 years
Amortizable intangible assets acquired			$ 5,343.3
Cash flow discount rate			14.50%
Questcor Pharmaceuticals, Inc. | Trademarks
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life			13 years
Amortizable intangible assets acquired			$ 5.2
Cash flow discount rate			10.00%
Questcor Pharmaceuticals, Inc. | Customer relationships
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life			12 years
Amortizable intangible assets acquired			$ 34.3
Cash flow discount rate			10.00%
Cadence Pharmaceuticals, Inc.
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired				$ 1,329.2
Intangible assets				$ 1,300.0
Cash flow discount rate				13.00%
Cadence Pharmaceuticals, Inc. | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life				8 years
Amortizable intangible assets acquired				$ 1,300.0
CNS Therapeutics, Inc.
Intangible Assets Acquired as Part of Business Combination [Line Items]
Net assets acquired					$ 91.7
Intangible assets					91.9
CNS Therapeutics, Inc. | In-process research and development
Intangible Assets Acquired as Part of Business Combination [Line Items]
Indefinite lived intangible assets acquired					18.6
Estimated cost to complete in-process research					$ 18.0
Cash flow discount rate					35.00%
CNS Therapeutics, Inc. | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life					13 years
Amortizable intangible assets acquired					$ 73.1
CNS Therapeutics, Inc. | Trademarks
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life					3 years
Amortizable intangible assets acquired					$ 0.2
Therakos Immunotherapy [Member] | Therakos | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Cash flow discount rate	17.00%
Inomax | Ikaria | Completed Technology
Intangible Assets Acquired as Part of Business Combination [Line Items]
Cash flow discount rate		14.50%
Terlipressin [Member] | Ikaria | In-process research and development
Intangible Assets Acquired as Part of Business Combination [Line Items]
Cash flow discount rate		17.00%